Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - aprepitant, quantity: 80 mg - capsule, hard - excipient ingredients: hypromellose; sodium lauryl sulfate; gelatin; titanium dioxide; poloxamer; microcrystalline cellulose; sucrose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - aprepitant in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:,? highly emetogenic cancer chemotherapy.,? moderately emetogenic cancer chemotherapy,aprepitant is indicated for the prevention of postoperative nausea and vomiting.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - aprepitant, quantity: 165 mg - capsule, hard - excipient ingredients: titanium dioxide; microcrystalline cellulose; gelatin; hypromellose; poloxamer; sucrose; sodium lauryl sulfate; indigo carmine aluminium lake; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - aprepitant in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:,? highly emetogenic cancer chemotherapy.,? moderately emetogenic cancer chemotherapy,aprepitant is indicated for the prevention of postoperative nausea and vomiting.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - aprepitant, quantity: 125 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; sucrose; hypromellose; poloxamer; gelatin; sodium lauryl sulfate; titanium dioxide; iron oxide red; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - aprepitant in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:,? highly emetogenic cancer chemotherapy.,? moderately emetogenic cancer chemotherapy,aprepitant is indicated for the prevention of postoperative nausea and vomiting.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - aprepitant, quantity: 40 mg - capsule, hard - excipient ingredients: iron oxide yellow; hypromellose; poloxamer; sucrose; gelatin; sodium lauryl sulfate; titanium dioxide; microcrystalline cellulose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - aprepitant in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:,? highly emetogenic cancer chemotherapy.,? moderately emetogenic cancer chemotherapy,aprepitant is indicated for the prevention of postoperative nausea and vomiting.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - nebivolol hydrochloride, quantity: 10.9 mg (equivalent: nebivolol, qty 10 mg) - tablet - excipient ingredients: lactose monohydrate; maize starch; croscarmellose sodium; hypromellose; polysorbate 80; microcrystalline cellulose; silicon dioxide; magnesium stearate - nebivolol is indicated: - to treat essential hypertension; - to treat stable chronic heart failure as an adjunct to standard therapies in patients 70 years or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - nebivolol hydrochloride, quantity: 1.363 mg (equivalent: nebivolol, qty 1.25 mg) - tablet - excipient ingredients: lactose monohydrate; maize starch; croscarmellose sodium; hypromellose; polysorbate 80; microcrystalline cellulose; silicon dioxide; magnesium stearate - nebivolol is indicated: - to treat essential hypertension; - to treat stable chronic heart failure as an adjunct to standard therapies in patients 70 years or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - agomelatine-citric acid, quantity: 44.739 mg (equivalent: agomelatine, qty mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; povidone; sodium stearylfumarate; mannitol; crospovidone; silicified microcrystalline cellulose; magnesium stearate; stearic acid; hypromellose; macrogol 6000; titanium dioxide; purified talc; iron oxide yellow - treatment of major depression in adults including prevention of relapse.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - anagrelide hydrochloride, quantity: 0.57 mg (equivalent: anagrelide, qty 0.5 mg) - capsule, hard - excipient ingredients: povidone; magnesium stearate; gelatin; lactose monohydrate; croscarmellose sodium; titanium dioxide; microcrystalline cellulose; lactose - anagrelide lupin capsules are indicated for the treatment of essential thrombocythaemia

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - atorvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - voriconazole -